Imugene Limited
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more
Imugene Limited (IUGNF) - Total Liabilities
Latest total liabilities as of June 2025: $38.56 Million USD
Based on the latest financial reports, Imugene Limited (IUGNF) has total liabilities worth $38.56 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Imugene Limited - Total Liabilities Trend (1993–2025)
This chart illustrates how Imugene Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Imugene Limited Competitors by Total Liabilities
The table below lists competitors of Imugene Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thunder Bridge Capital Partners IV Inc. Warrant
NASDAQ:THCPW
|
USA | $7.17 Million |
|
Arkle Resources PLC
STU:48O
|
Germany | €615.00K |
|
Star Fashion Culture Holdings Limited
NASDAQ:STFS
|
USA | $41.42 Million |
|
Union Dental Holdings Inc
OTCQB:XCRT
|
USA | $2.95 Million |
|
Terrain Minerals Ltd
AU:TMX
|
Australia | AU$566.54K |
|
Castle Peak Holdings Public Company Limited
BK:CPH
|
Thailand | ฿568.02 Million |
|
Plaza Centers NV
WAR:PLZ
|
Poland | zł162.91 Million |
|
Vaishali Pharma Limited
NSE:VAISHALI
|
India | ₹545.40 Million |
Liability Composition Analysis (1993–2025)
This chart breaks down Imugene Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Imugene Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Imugene Limited (1993–2025)
The table below shows the annual total liabilities of Imugene Limited from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $38.56 Million | +16.33% |
| 2024-06-30 | $33.14 Million | +345.66% |
| 2023-06-30 | $7.44 Million | -16.45% |
| 2022-06-30 | $8.90 Million | +31.06% |
| 2021-06-30 | $6.79 Million | +25.80% |
| 2020-06-30 | $5.40 Million | +54.93% |
| 2019-06-30 | $3.48 Million | +142.19% |
| 2018-06-30 | $1.44 Million | +12.15% |
| 2017-06-30 | $1.28 Million | -23.60% |
| 2016-06-30 | $1.68 Million | +21.45% |
| 2015-06-30 | $1.38 Million | -27.20% |
| 2014-06-30 | $1.90 Million | +172.09% |
| 2013-06-30 | $698.03K | +184.94% |
| 2012-06-30 | $244.97K | -48.99% |
| 2011-06-30 | $480.28K | +56.25% |
| 2010-06-30 | $307.37K | -29.62% |
| 2009-06-30 | $436.72K | -11.48% |
| 2008-06-30 | $493.37K | -11.99% |
| 2007-06-30 | $560.55K | -30.46% |
| 2006-06-30 | $806.04K | +95.87% |
| 2005-06-30 | $411.52K | -29.57% |
| 2004-06-30 | $584.29K | -16.62% |
| 2003-06-30 | $700.77K | +1259.15% |
| 2002-06-30 | $51.56K | -98.07% |
| 2001-06-30 | $2.67 Million | +195.33% |
| 2000-06-30 | $903.09K | +0.57% |
| 1999-06-30 | $898.00K | -20.95% |
| 1998-06-30 | $1.14 Million | -8.46% |
| 1997-06-30 | $1.24 Million | +10.12% |
| 1996-06-30 | $1.13 Million | -13.64% |
| 1995-06-30 | $1.30 Million | +927.56% |
| 1994-06-30 | $127.00K | -78.36% |
| 1993-06-30 | $587.00K | -- |